Abstract:Abstract The platelet fibrinogen receptor α IIbβ 3 exists in an equilibrium between inactive and active conformations. In its inactive conformation, the transmembrane (TM) domains of α IIb and β 3 interact, but they separate when α IIbβ 3 assumes its active conformation. Peptides corresponding to the α IIb TM domain form homodimers in vitro and in bacterial membranes and the interface that mediates this interaction overlaps with the interface that mediates the heteromeric association of the α IIb TM domain with that of β 3. Because the homomeric association of α IIb TM domain is relatively strong, we expected that peptides spanning the α IIb TM domain might activate α IIbβ 3 by binding to the α IIb TM domain, thereby disrupting the α IIb/β 3 TM domain heterodimer. We synthesized a 26 residue peptide corresponding to the α IIb TM domain, flanked by pairs of lysine residues to increase its solubility in water, and assessed its ability to activate washed or gel-filtered platelets in an aggregometer. Addition of 3 μM peptide induced platelet aggregation after a short lag, but unlike aggregation stimulated by ADP, peptide-induced aggregation was not preceded by platelet shape change. Nonetheless, like ADP-induced aggregation, peptide-induced aggregation was inhibited by EDTA and the α IIbβ 3-specific monoclonal antibody A2A9. On the other hand, pre-incubating platelets with PGE1 or apyrase caused only a small decrease in the rate and extent of peptide-induced aggregation, suggesting that the peptide induced aggregation by binding directly to α IIbβ 3. A peptide corresponding the β 3 TM domain behaved in an identical manner, whereas an unrelated peptide, the model TM domain MS-1, had no effect. Similarly, there was little response to an α IIb TM peptide in which glycines 972 and 976, the first and last residues of a GxxxG motif, were changed to leucine. Confirming that the α IIb TM peptide binds to α IIbβ 3, we found that a FITC-labeled α IIb TM peptide co-eluted with purified α IIbβ 3 during size exclusion gel filtration. To determine whether the latter interaction involved the α IIb TM domain, we used the TOXCAT assay. In TOXCAT, the α IIb TM domain-mediated dimerization of a fusion protein containing the α IIb TM domain interposed between maltose binding protein and the ToxR’ transcriptional activation domain in the inner membrane of E. coli drives the activation of the chloramphenicol acetyl transferase (CAT) gene. We found that adding the α IIb TM peptide to the bacterial growth medium consistently decreased CAT synthesis, implying that its presence impaired α IIb-mediated fusion protein dimerization. These results provide evidence for the presence of an α IIb/β 3 TM domain heterodimer in unstimulated human platelets and suggest that the GxxxG motif in the α IIb TM domain is involved in its formation. Because the homomeric interaction of α IIb and β 3 TM domains is substantially stronger than their heteromeric interaction, our data are also consistent with the hypothesis that the TM peptides disrupt the heterodimer which functions to maintain α IIbβ 3 in an inactive state. Lastly, the data suggest that stabilizing the α IIb/β 3 TM heterodimer may represent a new approach for the development of novel anti-platelet agents.

The Activation of Platelet Induced by the Venom of Trimeresurus Mucrosquamatus (from Hunan Province)

Resveratrol Attenuates Thromboxane A2 Receptor Agonist-Induced Platelet Activation by Reducing Phospholipase C Activity.

Induction of Platelet Activation by Cobra Venom Factor from Naja Naja Atra in Rat

Experimental study of interaction between activated VWF and targeted lipid microbubbles conjugated with recombinant GPⅠba

Effect of Protobothrops mucrosquamatus venom and its fractions on bIood coaguIation

[Purification of a Small Peptide SV-PP-3 from the Venom of Agkistrodon Blomhoffii Siniticus and Its Inhibition of Platelet Aggregation].

The in Vitro Inhibitory Effects of Brucea Javanica Oil on Platelet Aggregation and the Related Mechanism

Influence of Hexapeptide on Rabbit Platelet Aggregation Activity

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

[Purification and Characterization of Platelet Aggregation Inhibitor Component from Venom of Agkistrodon Halys Pallas].

Activation of Platelet α Iibβ 3 by Exogenous Peptides Corresponding to the Transmembrane Domains of α Iib and β 3.

Effect of Yiqi Huoxue Granules on Platelet Activation Induced by Thrombin

Purification and partial characterization of a novel phosphodiesterase from the venom of Trimeresurus stejnegeri: inhibition of platelet aggregation.

Some Characteristics of Mouse Platelet Aggregation and a Comparison of the Activity of a Range of Compounds in Mouse and Human Platelet-Rich Plasma in Vitro

Effects of Trihexyphenidyl on Aggregation and Intracellular Free Calcium Concentration in Human Platelets

Viper venoms drive the macrophages and hepatocytes to sequester and clear platelets: novel mechanism and therapeutic strategy for venom-induced thrombocytopenia

Platelet Desialylation Is a Novel Mechanism and Therapeutic Target in Daboia siamensis and Agkistrodon halys Envenomation-Induced Thrombocytopenia

Prostaglandin A1 Inhibits Increases in Intracellular Calcium Concentration, TXA2 Production and Platelet Activation1

Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A2 activity with varespladib

Influence of hexapeptide on platelet aggregation function in dog

20-Hydroxyeicosatetraenoic Acid Involved in Endothelial Activation and Thrombosis